Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Oral Health
Published in: BMC Oral Health 1/2021

Open Access 01-12-2021 | Research

CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats

Authors: Guohui Bai, Hang Yu, Xiaoyan Guan, Fengjiao Zeng, Xia Liu, Bin Chen, Jianguo Liu, Yuan Tian

Published in: BMC Oral Health | Issue 1/2021

Login to get access

Abstract

Background

We previously demonstrated that nasal administration of periodontitis gene vaccine (pVAX1-HA2-fimA) or pVAX1-HA2-fimA plus IL-15 as adjuvant provoked protective immunity in the periodontal tissue of SD rats. This study evaluated the immune effect of pVAX1-HA2-fimA plus CpG-ODN 1826 as an adjuvant in the SD rat periodontitis models to improve the efficacy of the previously used vaccine.

Methods

Periodontitis was induced in maxillary second molars in SD rats receiving a ligature and infected with Porphyromonas gingivalis. Forty-two SD rats were randomly assigned to six groups: A, control without P. gingivalis; B, P. gingivalis with saline; C, P. gingivalis with pVAX1; D, P. gingivalis with pVAX1-HA2-fimA; E, P. gingivalis with pVAX1-HA2-fimA/IL-15; F, P. gingivalis with pVAX1-HA2-fimA+CpG ODN 1826 (30 µg). The levels of FimA-specific and HA2-specific secretory IgA antibodies in the saliva of rats were measured by ELISA. The levels of COX-2 and RANKL were detected by immunohistochemical assay. Morphometric analysis was used to evaluate alveolar bone loss. Major organs were observed by HE staining.

Results

30 μg could be the optimal immunization dose for CpG-ODN 1826 and the levels of SIgA antibody were consistently higher in the pVAX1-HA2-fimA+CpG-ODN 1826 (30 µg) group than in the other groups during weeks 1–8 (P < 0.05, except week 1 or 2). Morphometric analysis demonstrated that pVAX1-HA2-fimA+CpG-ODN 1826 (30 µg) significantly reduced alveolar bone loss in ligated maxillary molars in group F compared with groups B–E (P < 0.05). Immunohistochemical assays revealed that the levels of COX-2 and RANKL were significantly lower in group F compared with groups B–E (P < 0.05). HE staining results of the major organs indicated that pVAX1-HA2-fimA with or without CpG-ODN 1826 was not toxic for in vivo use.

Conclusions

These results indicated that CpG-ODN 1826 (30 µg) could be used as an effective and safe mucosal adjuvant for pVAX1-HA2-fimA in SD rats since it could elicit mucosal SIgA responses and modulate COX-2 and RANKL production during weeks 1–8, thereby inhibiting inflammation and decreasing bone loss.
Literature
1.
2.
Mei F, Xie M, Huang X, Long Y, Lu X, Wang X, Chen L. Porphyromonas gingivalis and its systemic impact: current status. Pathogens (Basel, Switzerland). 2020;9(11):944.
3.
Passos-Soares J, Vianna M, Gomes-Filho I, Cruz S, Barreto M, Adan L, Rösing C, Trindade S, Cerqueira E, Scannapieco F. Association between osteoporosis treatment and severe periodontitis in postmenopausal women. Menopause: J North Ame Menopause Soc. 2017;24(7):789–95.CrossRef
4.
Shrihari T. Potential correlation between periodontitis and coronary heart disease—an overview. Gen Dent. 2012;60(1):20–4.PubMed
5.
Xu W, Zhou W, Wang H, Liang S. Roles of Porphyromonas gingivalis and its virulence factors in periodontitis. Adv Protein Chem Struct Biol. 2020;120:45–84.PubMedPubMedCentralCrossRef
6.
Hajishengallis G. Immunomicrobial pathogenesis of periodontitis: keystones, pathobionts, and host response. Trends Immunol. 2014;35(1):3–11.PubMedCrossRef
7.
Mysak J, Podzimek S, Sommerova P, Lyuya-Mi Y, Bartova J, Janatova T, Prochazkova J, Duskova J. Porphyromonas gingivalis: major periodontopathic pathogen overview. J Immunol Res. 2014;2014:476068.PubMedPubMedCentralCrossRef
8.
Bramanti T, Holt S. Roles of porphyrins and host iron transport proteins in regulation of growth of Porphyromonas gingivalis W50. J Bacteriol. 1991;173(22):7330–9.PubMedPubMedCentralCrossRef
9.
DeCarlo A, Paramaesvaran M, Yun P, Collyer C, Hunter N. Porphyrin-mediated binding to hemoglobin by the HA2 domain of cysteine proteinases (gingipains) and hemagglutinins from the periodontal pathogen Porphyromonas gingivalis. J Bacteriol. 1999;181(12):3784–91.PubMedPubMedCentralCrossRef
10.
Smalley J, Olczak T. Heme acquisition mechanisms of Porphyromonas gingivalis—strategies used in a polymicrobial community in a heme-limited host environment. Mol Oral Microbiol. 2017;32(1):1–23.PubMedCrossRef
11.
Hasegawa Y, Nagano K, Yoshida YF. A major fimbrilin variant of Mfa1 fimbriae in Porphyromonas gingivalis. J Dental Res Off Publ Int Assoc Dental Res. 2015;94(8):1143–8.
12.
Hasegawa Y, Iijima Y, Persson K, Nagano K, Yoshida Y, Lamont R, Kikuchi T, Mitani A, Yoshimura F. Role of Mfa5 in expression of Mfa1 fimbriae in Porphyromonas gingivalis. J Dental Res. 2016;95(11):1291–7.CrossRef
13.
14.
Wang H, Zhang W, Wang W, Zhang L. The prevalence of fimA genotypes of Porphyromonas gingivalis in patients with chronic periodontitis: a meta-analysis. PLoS ONE. 2020;15(10):e0240251.PubMedPubMedCentralCrossRef
15.
Bai G, Chen J, Miao C, Yang L, Tian Y, Liu J. The study on the construction and expression of the recombinant plasmids of Porphyromonas gingivalis HA2 gene and interleukin IL-15 gene. Genom Appl Biol. 2019;38(2):675–664.
16.
Bai G, Miao C, Jing C, Zeng F, Yuan T, Liu J. The study of construction and expression of periodontitis gene vaccine against Porphyromonas gingivalis. Genom Appl Biol. 2018;37(11):5165–73.
17.
Bai G, Zeng F, Yang L, Chen J, Liu J, Tian Y. Experimental study on gene vaccine pVAX1-HA2-FimA and pVAX1-HA2-FimA/IL-15 by intranasal immunization in rat. J Pract Stomatol. 2020;36(2):275–9.
18.
Yu H, Yang Z, Zeng F, Chen J, Liu J, Bai P, Bai G. Protective effects of periodontitis gene vaccine pVAX1-HA2-FimA/IL-15 and pVAX1-HA2-FimA in rats with experimental periodontitis. J Nanjing Med Univ (Nat Sci). 2020;40(2):195–9.
19.
Kataoka K, Kawabata S, Koyanagi K, Hashimoto Y, Miyake T, Fujihashi K. Porphyromonas gingivalis respiratory FimA-specific secretory IgA antibodies upregulated by DC-targeting nasal double DNA adjuvant are essential for elimination of. Front Immunol. 2021;12:634923.PubMedPubMedCentralCrossRef
20.
Khodadadi M, Ghaffarifar F, Dalimi A, Ahmadpour E. Immunogenicity of in-silico designed multi-epitope DNA vaccine encoding SAG1, SAG3 and SAG5 of Toxoplasma gondii adjuvanted with CpG-ODN against acute toxoplasmosis in BALB/c mice. Acta Trop. 2021;216:105836.PubMedCrossRef
21.
Ribes S, Zacke L, Nessler S, Saiepour N, Avendaño-Guzmán E, Ballüer M, Hanisch U, Nau R. Oligodeoxynucleotides containing unmethylated cytosine-guanine motifs are effective immunostimulants against pneumococcal meningitis in the immunocompetent and neutropenic host. J Neuroinflammation. 2021;18(1):39.PubMedPubMedCentralCrossRef
22.
Scheiermann J, Klinman D. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine. 2014;32(48):6377–89.PubMedPubMedCentralCrossRef
23.
Shirota H, Klinman D. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines. 2014;13(2):299–312.PubMedCrossRef
24.
Tateishi K, Fujihashi K, Yamamoto N, Hasegawa H, Ainai A, Sato K, Iho S, Yamamoto S, Maeyama J, Odagiri T, et al. CpG ODN G91 as a novel nasal ODN adjuvant elicits complete protection from influenza virus infection without causing inflammatory immune responses. Vaccine. 2019;37(36):5382–9.PubMedCrossRef
25.
Pohar J, Lainšček D, Kunšek A, Cajnko M, Jerala R, Benčina M. Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9. Sci Rep. 2017;7(1):14598.PubMedPubMedCentralCrossRef
26.
27.
Jie J, Zhang Y, Zhou H, Zhai X, Zhang N, Yuan H, Ni W, Tai G. CpG ODN1826 as a promising mucin1-maltose-binding protein vaccine adjuvant induced DC maturation and enhanced antitumor immunity. Int J Mol Sci. 2018;19(3):920.PubMedCentralCrossRef
28.
Kaewraemruaen C, Sermswan R, Wongratanacheewin S. CpG oligodeoxynucleotides with crude parasite antigens reduce worm recovery in Opisthorchis viverrini infected hamsters. Acta Trop. 2016;164:395–401.PubMedCrossRef
29.
Müller T, Becker E, Stallmann S, Waldhuber A, Römmler-Dreher F, Albrecht S, Mohr F, Hegemann J, Miethke T. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology. Vaccine. 2017;35(21):2801–10.PubMedCrossRef
30.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey M, Baker M, Browne W, Clark A, Cuthill I, Dirnagl U, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Physiol. 2020;598(18):3793–801.PubMedCrossRef
31.
Zeng F, Yang L, Liu J, Yu H, Chen J, Bai G (2019) Experiment of the periodontitis gene vaccine pVAX1-HA2-FimA and pVAX1-HA2-FimA/IL-15 by intranasal immunization in SD rats. Chongqing Med 48(10):1621–1624, 1629.
32.
Luo D, Dong X, Huang J, Huang C, Fang G, Huang Y. Pueraria lobata root polysaccharide alleviates glucose and lipid metabolic dysfunction in diabetic db/db mice. Pharm Biol. 2021;59(1):382–90.PubMedPubMedCentralCrossRef
33.
Yang S, Cheng J, Man C, Jiang L, Long G, Zhao W, Zheng D. Effects of exogenous nerve growth factor on the expression of BMP-9 and VEGF in the healing of rabbit mandible fracture with local nerve injury. J Orthop Surg Res. 2021;16(1):74.PubMedPubMedCentralCrossRef
34.
35.
36.
Meyle J. Chapple I (2015) Molecular aspects of the pathogenesis of periodontitis. Periodontol. 2000;69(1):7–17.CrossRef
37.
Jia L, Han N, Du J, Guo L, Luo Z, Liu Y. Porphyromonas gingivalis pathogenesis of important virulence factors of via toll-like receptors. Front Cell Infect Microbiol. 2019;9:262.PubMedPubMedCentralCrossRef
38.
Kong F, Zheng D, She P, Ni P, Zhu H, Xu H, Su Z. Porphyromonas gingivalis B cell antigen epitope vaccine, pIRES-ragB’-mGITRL, promoted RagB-specific antibody production and Tfh cells expansion. Scand J Immunol. 2015;81(6):476–82.PubMedCrossRef
39.
Nakao R, Hasegawa H, Dongying B, Ohnishi M, Senpuku H. Assessment of outer membrane vesicles of periodontopathic bacterium Porphyromonas gingivalis as possible mucosal immunogen. Vaccine. 2016;34(38):4626–34.PubMedCrossRef
40.
O’Brien-Simpson N, Holden J, Lenzo J, Tan Y, Brammar G, Walsh K, Singleton W, Orth R, Slakeski N, Cross K, et al. Porphyromonas gingivalis A therapeutic gingipain vaccine induces neutralising IgG1 antibodies that protect against experimental periodontitis. NPJ Vaccines. 2016;1:16022.PubMedPubMedCentralCrossRef
41.
Puth S, Hong S, Na H, Lee H, Lee Y, Kim S, Tan W, Hwang H, Sivasamy S, Jeong K, et al. A built-in adjuvant-engineered mucosal vaccine against dysbiotic periodontal diseases. Mucosal Immunol. 2019;12(2):565–79.PubMedCrossRef
42.
Sharma A, Honma K, Evans R, Hruby D, Genco R. Oral immunization with recombinant Streptococcus gordonii expressing Porphyromonas gingivalis FimA domains. Infect Immunity. 2001;69(5):2928–34.CrossRef
43.
Ishii K, Coban C, Akira S. Manifold mechanisms of Toll-like receptor-ligand recognition. J Clin Immunol. 2005;25(6):511–21.PubMedCrossRef
44.
Liu Z, Lei X, Li X, Cai J, Gao F, Yang Y. Toll-like receptors and radiation protection. Eur Rev Med Pharmacol Sci. 2018;22(1):31–9.PubMed
45.
Makita Y, Suzuki H, Kano T, Takahata A, Julian B, Novak J, Suzuki Y. TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. Kidney Int. 2020;97(2):340–9.PubMedCrossRef
46.
47.
Hu Y, Smith D, Frazier E, Zhao Z, Zhang C. Toll-like receptor 9 agonists as adjuvants for nanoparticle-based nicotine vaccine. Mol Pharm. 2021;18(3):1293–304.PubMedCrossRef
48.
Liu C, Hashizume T, Kurita-Ochiai T, Fujihashi K, Yamamoto M. Oral immunization with Porphyromonas gingivalis outer membrane protein and CpGoligodeoxynucleotides elicits T helper 1 and 2 cytokines for enhanced protective immunity. Mol Oral Microbiol. 2010;25(3):178–89.PubMedPubMedCentralCrossRef
49.
Guimarães M, Melo I, Adriano Araújo V, Tenazoa Wong D, Roriz Fonteles C, Moreira Leal L, Ribeiro R, Lima V. Dry extract of Matricaria recutita L. (Chamomile) prevents ligature-induced alveolar bone resorption in rats via inhibition of tumor necrosis factor-α and interleukin-1β. J Periodontol. 2016;87(6):706–15.PubMedCrossRef
50.
Ricciotti E, FitzGerald G. Prostaglandins and inflammation. Arterioscler Thrombosi Vasc Biol. 2011;31(5):986–1000.CrossRef
51.
Jagadish R, Mehta D. Comparative evaluation of the efficacy of the cyclooxygenase pathway inhibitor and nitric oxide synthase inhibitor in the reduction of alveolar bone loss in ligature induced periodontitis in rats: an experimental study. J Indian Soc Periodontol. 2014;18(1):59–64.PubMedPubMedCentralCrossRef
52.
Moro M, Oliveira M, Oliveira L, Teixeira S, Muscará M, Spolidorio L, Holzhausen M. Effects of selective versus non-selective COX-2 inhibition on experimental periodontitis. Braz Dental J. 2019;30(2):133–8.CrossRef
53.
Chen B, Wu W, Sun W, Zhang Q, Yan F, Xiao Y. RANKL expression in periodontal disease: where does RANKL come from? BioMed Res Int. 2014;2014:731039.PubMedPubMedCentral
54.
Kim K, Cho M, Lee S, Oh H, Kang C, Ju J, Min S, Cho Y, Park S, Kim H. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity by activating RANKL via TLR-2 and TLR-4 activation. Immunol Lett. 2007;110(1):54–64.PubMedCrossRef
55.
Han X, Lin X, Yu X, Lin J, Kawai T, Larosa KB, Taubman MA. Porphyromonas gingivalis infection-associated periodontal bone resorption is dependent on receptor activator of NF-κB ligand. Infect Immun. 2013;81(5):1502–9.PubMedPubMedCentralCrossRef
56.
Sikora A, Gomez C, Le Van A, Baarda B, Darnell S, Martinez F, Zielke R, Bonventre J, Jerse A. A novel gonorrhea vaccine composed of MetQ lipoprotein formulated with CpG shortens experimental murine infection. Vaccine. 2020;38(51):8175–84.PubMedCrossRefPubMedCentral
57.
Blake S, Bremer P, Zhou B, Petrovsky N, Smith L, Hwang C, Janda K. Developing translational vaccines against heroin and fentanyl through investigation of adjuvants and stability. Mol Pharm. 2021;18(1):228–35.PubMedCrossRef
Metadata
Title
CpG immunostimulatory oligodeoxynucleotide 1826 as a novel nasal ODN adjuvant enhanced the protective efficacy of the periodontitis gene vaccine in a periodontitis model in SD rats
Authors
Guohui Bai
Hang Yu
Xiaoyan Guan
Fengjiao Zeng
Xia Liu
Bin Chen
Jianguo Liu
Yuan Tian
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2021
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/s12903-021-01763-1

Other articles of this Issue 1/2021

BMC Oral Health 1/2021 Go to the issue

Research article

Oral health knowledge and dental behavior among individuals with autism in Jordan: a case–control study

Research

Shaping ability of three nickel-titanium rotary instruments in simulated L-shaped canals: OneShape, Hero Shaper, and Revo-S

Research

The prevalence of denture stomatitis in cigarette and hookah smokers and opium addicts: findings from Rafsanjan Cohort Study

Research article

Clinico-pathological study of malignant odontogenic tumours from a national referral centre

Research

Validation of an instrument to determine oral health knowledge, attitudes, and practices during pregnancy

Research article

The inflammation link between periodontal disease and coronary atherosclerosis in patients with acute coronary syndromes: case–control study